Chemistry:LY-503430
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | LY-503430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide |
| Routes of administration | Oral |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H25FN2O3S |
| Molar mass | 392.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
LY-503430 is an AMPA receptor positive allosteric modulator developed by Eli Lilly.[1]
LY-503430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus, and striatum.[2][3] It is orally active and the main application it is currently being developed for is treatment of Parkinson's disease, although it has also been proposed to be useful in the treatment of Alzheimer's disease, depression, and schizophrenia.[4][5]
See also
References
- ↑ "LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease". CNS Drug Reviews 11 (1): 77–96. 2005. doi:10.1111/j.1527-3458.2005.tb00037.x. PMID 15867954.
- ↑ "LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics 306 (2): 752–62. August 2003. doi:10.1124/jpet.103.049445. PMID 12730350.
- ↑ "Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors". The Journal of Pharmacology and Experimental Therapeutics 319 (1): 293–8. October 2006. doi:10.1124/jpet.106.105734. PMID 16803862.
- ↑ "AMPA receptor potentiators for the treatment of CNS disorders". Current Drug Targets. CNS and Neurological Disorders 3 (3): 181–94. June 2004. doi:10.2174/1568007043337508. PMID 15180479.
- ↑ "AMPA receptor potentiators: application for depression and Parkinson's disease". Current Drug Targets 8 (5): 603–20. May 2007. doi:10.2174/138945007780618517. PMID 17504104.
 |  |
